Project Cure CRC
The Alliance is on a mission to end colorectal cancer. With Project Cure CRC, we’re funding research to make it happen.
Project Cure CRC addresses an urgent need
Colorectal cancer claims more than 50,000 lives annually in the U.S., with a 13% survival rate for metastatic disease. Despite rising cases in young adults, research funding lags behind, threatening to make CRC the deadliest cancer under 50 by 2030.
Our plan to find cures
We initiated Project Cure CRC to make a difference in outcomes for the millions of people affected by this disease, and we are committed to working with experts, industry, and donors to achieve that goal.
A $100 million commitment
Project Cure CRC is making available tens of millions of dollars to innovators whose work aims to expedite colorectal cancer research to a curable science.
Innovation is in progress
Project Cure CRC has already invested millions of dollars into promising high-risk/high-reward research.
Seeking visionaries
Ending colorectal cancer will take broad collaboration. The Alliance seeks supporters and researchers to advance Project Cure CRC.
Up Next
The breakthrough fundTop resources
Alliance and GCAR Announce Collaboration to Advance a Groundbreaking Adaptive Clinical Trial Platform for CRC: KLEOS
A first-of-its-kind trial platform in the colorectal cancer space, Project Cure CRC’s KLEOS is being driven by the Colorectal Cancer Alliance, the leading nonprofit dedicated to ending the disease, in collaboration with GCAR, a pioneer in the design and implementation of innovative clinical trials.
Alliance Presents Poster Sessions & Speaks at Symposium During AACR Annual Meeting
The Colorectal Cancer Alliance will present three poster sessions and deliver an oral presentation at the American Association for Cancer Research Annual Meeting 2026.
Where breakthroughs begin: Project Cure CRC spotlight on Dr. Lisa Mielke
hrough Project Cure CRC, the Alliance is fueling bold, early-stage research with the potential to transform colorectal cancer treatment. Dr. Lisa Mielke’s groundbreaking work explores how the gut’s immune system and nerve signaling influence cancer growth—opening the door to new therapeutic approaches, including repurposed existing drugs. This is what’s possible when promising ideas get the support they need to move forward.